Search research articles
Contact Us
Filters
Showing results (151-160 of 272) with videos related to
Page
of 28
Sort By:
Molecular Cancer Therapeutics
|
November 6, 2009
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S Bekaii-Saab, Julie M Roda, Kristan D Guenterberg, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 20, 2015
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies
Malori A Lankenau, Ravi Patel, Sandya Liyanarachchi, et al.
Annals of Surgical Oncology
|
May 8, 2003
Patterns of recurrence after sentinel lymph node biopsy for breast cancer
Brian D Badgwell, Stephen P Povoski, Shahab F Abdessalam, et al.
Arthritis Research & Therapy
|
November 19, 2013
Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta
Yong Seok Choi, Jin Kyun Park, Eun Ha Kang, et al.
Annals of Surgical Oncology
|
May 31, 2007
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
Kimberly A Varker, Jennifer E Biber, Cheryl Kefauver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells
Gregory B Lesinski, John Trefry, Melanie Brasdovich, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 3, 2011
Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment
Hongyan He, Valerie Grignol, Volodymyr Karpa, et al.
Cancer Immunology Research
|
January 8, 2025
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
Emily Schwarz, Himanshu Savardekar, Sara Zelinskas, et al.
Cancer Immunology Research
|
July 5, 2014
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival
William E Carson, Joseph M Unger, Jeffrey A Sosman, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
May 27, 2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, et al.
Page
of 28
Search research articles
Search
Showing results (151-160 of 272) with videos related to
Sort By:
Page
of 28
Molecular Cancer Therapeutics
|
November 6, 2009
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S Bekaii-Saab, Julie M Roda, Kristan D Guenterberg, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 20, 2015
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies
Malori A Lankenau, Ravi Patel, Sandya Liyanarachchi, et al.
Annals of Surgical Oncology
|
May 8, 2003
Patterns of recurrence after sentinel lymph node biopsy for breast cancer
Brian D Badgwell, Stephen P Povoski, Shahab F Abdessalam, et al.
Arthritis Research & Therapy
|
November 19, 2013
Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta
Yong Seok Choi, Jin Kyun Park, Eun Ha Kang, et al.
Annals of Surgical Oncology
|
May 31, 2007
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
Kimberly A Varker, Jennifer E Biber, Cheryl Kefauver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells
Gregory B Lesinski, John Trefry, Melanie Brasdovich, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 3, 2011
Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment
Hongyan He, Valerie Grignol, Volodymyr Karpa, et al.
Cancer Immunology Research
|
January 8, 2025
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
Emily Schwarz, Himanshu Savardekar, Sara Zelinskas, et al.
Cancer Immunology Research
|
July 5, 2014
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival
William E Carson, Joseph M Unger, Jeffrey A Sosman, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
May 27, 2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, et al.
Page
of 28